Clinical trials: Asthma; Eosinophilic
Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA)
Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment
The rationale of the roll-over study (ROSY) is to provide continuous access to study treatment for participants who have completed or exited a parent study and are deemed appropriate for continued benralizumab treatment, as…
- Conditions
- Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES)
- Trial name
- ROSY-F (NCT07444567)
- Testing
- Benralizumab
- Where
- 47 sites in United States, Argentina and 12 more
- Volunteers
- 230 people
- Sponsor
- AstraZeneca
Asthma
Efficacy and Safety Study of Reslizumab to Treat Poorly Controlled Asthma
The purpose of this study is to determine the effectiveness and safety of reslizumab in the treatment of subjects with poorly controlled asthma.
- Trial name
- NCT00587288
- Testing
- Reslizumab, Saline
- Where
- 30 sites in United States, Canada
- Volunteers
- 106 people
- Sponsor
- Ception Therapeutics
Eosinophilic Asthma
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment
This study evaluates the efficacy and safety of benralizumab as an add-on therapy in uncontrolled eosinophilic asthma participants treated with medium-dose ICS-LABA compared to the conventional treatment step of escalation of…
- Trial name
- BRISOTE (NCT06750289)
- Testing
- ICS-LABA, benralizumab
- Where
- 86 sites in United States, Bulgaria and 11 more
- Volunteers
- 130 people
- Sponsor
- AstraZeneca
Eosinophils, Asthma
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
This is a multicenter, open-label (OL) extension study to obtain additional long-term safety data for subcutaneous (sc) administration of reslizumab treatment administered at a fixed dose of 110 mg in patients 12 years of age and…
- Trial name
- NCT03052725
- Testing
- reslizumab
- Where
- 134 sites in United States, Belgium and 11 more
- Volunteers
- 391 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Severe Eosinophilic Asthma, Nasal Polyps
RANS. Study in Patients With Severe Eosinophilic Asthma and Nasal Polyps.
The purpose of this observational study is to describe the population of patients with SEA + NP who have been prescribed FASENRA and assess available clinical outcomes for both NP and asthma.
- Trial name
- RANS (NCT05180357)
- Testing
- FASENRA(benralizumab)
- Where
- 45 sites in United States, France and 4 more
- Volunteers
- 273 people
- Sponsor
- AstraZeneca
Asthma
Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma
Primary Objective: To investigate the effects of Dupilumab (SAR231893/REGN668) administered subcutaneously (SC) once weekly (qw) for 12 weeks as compared to placebo on reducing the incidence of asthma exacerbation in participants…
- Trial name
- NCT01312961
- Testing
- Dupilumab, Fluticasone/Salmeterol combination therapy, Fluticasone monotherapy
- Where
- 50 sites in United States
- Volunteers
- 104 people
- Sponsor
- Sanofi
Non-Eosinophilic Asthma
A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma.
The primary objective of this study is to evaluate the efficacy of AVTX-002 compared with placebo in patients with poorly controlled non-eosinophilic asthma (NEA).
- Trial name
- NCT05288504
- Testing
- AVTX-002
- Where
- 24 sites in United States
- Volunteers
- 91 people
- Sponsor
- Avalo Therapeutics, Inc.
Asthma
A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype
This study will assess the efficacy and safety of GSK3511294 (Depemokimab) as an adjunctive therapy in participants with severe uncontrolled asthma with an eosinophilic phenotype.
- Trial name
- SWIFT-2 (NCT04718103)
- Testing
- GSK3511294
- Where
- 129 sites in United States, Australia and 9 more
- Volunteers
- 397 people
- Sponsor
- GlaxoSmithKline
Asthma; Eosinophilic
Efficacy and Safety of CHF 6532 in Patients With Uncontrolled Severe Eosinophilic Asthma
The purpose of this phase III Study is to demonstrate the efficacy of at least one dose of CHF 6532 on moderate and severe asthma exacerbations rate compared to placebo.
- Trial name
- PERSEA (NCT04049175)
- Testing
- Treatment A, Treatment B, Treatment C
- Where
- Bulgaria
- Volunteers
- 810 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Eosinophilic Esophagitis
Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2)
This is a 2-part randomized, double-blind, placebo-controlled study followed by an open-label extension (OLE) of APT-1011 in adults with EoE.
- Trial name
- FLUTE-2 (NCT04281108)
- Testing
- APT-1011, Esophagogastroduodenoscopy
- Where
- 56 sites in United States, Australia and 1 more
- Volunteers
- 143 people
- Sponsor
- Ellodi Pharmaceuticals, LP
Asthma
BURAN: Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma Using Functional Respiratory Imaging
This study will assess the effects of benralizumab on airway dynamics in severe eosinophilic asthma in terms of quantitative computed tomography (CT)-derived measurements of pulmonary structure and function using the Functional…
- Trial name
- BURAN (NCT05552508)
- Testing
- Benralizumab
- Where
- 25 sites in United States, Australia and 5 more
- Volunteers
- 45 people
- Sponsor
- AstraZeneca
Uncontrolled and Suspected Eosinophilic Asthma
A Phase IIa Study of KHK4563
This is a double-blind, placebo-controlled dose-ranging study of KHK4563 to evaluate the effect of multiple-dose subcutaneous administration of KHK4563 on the annual asthma exacerbation rate in adult subjects with uncontrolled…
- Trial name
- 4563-003 (NCT01412736)
- Testing
- KHK4563
- Where
- 29 sites in Japan, South Korea
- Volunteers
- 106 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Severe Eosinophilic Asthma
Real World Evidence of Benralizumab in Eosinophilic Severe AsThma in Russia (BEST)
Benralizumab is a humanised, afucosylated, monoclonal antibody against the interleukin (IL)-5 receptor (IL-5R) α subunit that induces direct, rapid, and near-complete depletion of eosinophils in blood, airway tissue, and bone…
- Trial name
- NCT05271526
- Where
- Russia
- Volunteers
- 3 people
- Sponsor
- AstraZeneca
Severe Asthma
Prevalence of the Eosinophilic Phenotype Among Severe Asthma Patients
The purpose of this cross-sectional, multicenter study is to determine the prevalence of an eosinophilic phenotype of blood eosinophil count ≥ 300 cells/mm3 among severe asthma patients who attend to sites specialized in the…
- Trial name
- PREPARE (NCT03931954)
- Where
- 18 sites in Argentina, Chile and 4 more
- Volunteers
- 794 people
- Sponsor
- AstraZeneca
Asthma With Eosinophilic Phenotype
A Study Comparing a Pre-filled Safety Syringe and an Autoinjector for SHR-1703 Injection in Healthy Participants
This is a single-center, randomized, parallel-group, open-label clinical study designed to compare the bioavailability and safety of SHR-1703 Injection administered subcutaneously using a pre-filled safety syringe (PFS) or a…
- Trial name
- NCT07701239
- Testing
- SHR-1703 Injection
- Where
- China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Asthma
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma
A study to evaluate the efficacy and safety of benralizumab administered subcutaneously in patients ≥ 6 to < 18 years of age with severe eosinophilic asthma, including a well-documented history of asthma exacerbations and…
- Trial name
- DOMINICA (NCT05692180)
- Testing
- Benralizumab
- Where
- 43 sites in United States, Argentina and 7 more
- Volunteers
- 94 people
- Sponsor
- AstraZeneca
Asthma
A Phase II Study of 610 in Participants With Severe Eosinophilic Asthma
This study will assess the efficacy and safety of 610 as an adjunctive therapy in adult subjects with severe eosinophilic asthma.
- Trial name
- NCT05528679
- Testing
- 610 100mg, 610 300mg
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Asthma
A Study to Test if TEV-53275 is Effective in Relieving Asthma
The primary objective of the study is to evaluate the efficacy of TEV-53275 administered subcutaneously (sc) in adult participants with persistent asthma and an eosinophilic phenotype compared to placebo.
- Trial name
- NCT04847674
- Testing
- TEV-53275 Dose A, TEV-53275 Dose B
- Where
- 82 sites in United States, Canada
- Volunteers
- 97 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
Efficacy and Safety Study of 610 in Patients With Severe Asthma
The primary objective of the study is to evaluate the efficacy and safety of 610 in Chinese adults with severe asthma.
- Trial name
- NCT06323213
- Testing
- 610
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Asthma
A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benralizumab in Severe, Uncontrolled Asthma Patients With Eosinophilic Inflammation
The purpose of this study is to investigate the onset and maintenance of effect of benralizumab on lung function, blood eosinophils, asthma control metrics and quality of life during 12-week treatment in patients with…
- Trial name
- SOLANA (NCT02869438)
- Testing
- Benralizumab
- Where
- 54 sites in United States, Chile and 4 more
- Volunteers
- 233 people
- Sponsor
- AstraZeneca